| answer text |
<p>The Life Sciences Industrial Strategy set out our vision of being a world-leader
in developing and bringing to market innovative medicines to improve life-chances
of United Kingdom patients. It highlighted the importance of evolving and simplifying
the access system for new medicines by implementing, and building on, the findings
of the Accelerated Access Review.</p><p> </p><p>The Early Access to Medicines Scheme
(EAMS) is an essential part of delivering on this ambition. It has been effective
in encouraging companies to bring their products to the UK and market them. The figures
below show increasing engagement from industry as the scheme has progressed.</p><p>
</p><table><tbody><tr><td><p>Year</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>Number
of Promising Innovative Medicines awarded</p></td><td><p>8</p></td><td><p>6</p></td><td><p>17</p></td><td><p>20</p></td></tr><tr><td><p>Number
of Scientific Opinions awarded</p></td><td><p>1</p></td><td><p>8</p></td><td><p>3</p></td><td><p>7</p></td></tr></tbody></table><p>
</p><p>The EAMS task group has been established to provide a forum for industry to
engage with the Government, the devolved administrations and arm’s length bodies,
driving further improvements to the scheme and making the UK a more attractive place
to test and deliver new pharmaceuticals.</p>
|
|
